Predicted effects of treatment for HCV infection vary among European countries

Gastroenterology

Volumn 143, Issue 4, 2012, Pages

  Deuffic Burban, Sylvie ^a,b   Deltenre, Pierre ^c,d   Buti, Maria ^e   Stroffolini, Tommaso ^f   Parkes, Julie ^g   Mühlberger, Nikolai ^h   Siebert, Uwe ^h,i,j   Moreno, Christophe ^k   Hatzakis, Angelos ^l   Rosenberg, William ^m   Zeuzem, Stefan ⁿ   Mathurin, Philippe ^a,c  

^a UNIV LILLE   (France)

^b UNIV LILLE   (France)

^c LILLE UNIVERSITY HOSPITAL   (France)

^d Hospital de Jolimont   (Belgium)

^e HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^f POLICLINICO UMBERTO I   (Italy)

^g UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^h UNIVERSITY FOR HEALTH SCIENCES   (Austria)

ⁱ HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^j Center for Personalized Cancer Medicine GmbH   (Austria)

^k ERASME HOSPITAL   (Belgium)

^l UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^m UNIVERSITY COLLEGE LONDON   (United Kingdom)

ⁿ UNIVERSITY HOSPITAL FRANKFURT   (Germany)

more..

Author keywords

Direct Acting Antiviral Agents; Epidemiology Analysis; Ribavirin; Treatment Outcomes

Indexed keywords

PEGINTERFERON; PROTEINASE INHIBITOR;

ADULT; AGED; ALCOHOL CONSUMPTION; ANTIVIRAL THERAPY; ARTICLE; BELGIUM; CONTROLLED STUDY; DEATH; DISEASE COURSE; FEMALE; FRANCE; GENOTYPE; GERMANY; HEALTH CARE POLICY; HEPATITIS C; HUMAN; INCIDENCE; ITALY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; MORTALITY; PREVALENCE; PRIORITY JOURNAL; SCREENING; SPAIN; TREATMENT RESPONSE; UNITED KINGDOM;

EID: 84866672248     PISSN: 00165085     EISSN: 15280012     Source Type: Journal    
DOI: 10.1053/j.gastro.2012.05.054     Document Type: Article

References (120)

1. G.L. Armstrong, M.J. Alter, G.M. McQuillan The past incidence of hepatitis C virus infection: implications for the future burden of chronic liver disease in the United States Hepatology 31 2000 777 782
2. S. Deuffic, L. Buffat, T. Poynard Modeling the hepatitis C virus epidemic in France Hepatology 29 1999 1596 1601
3. G.L. Davis, J.E. Albright, S.F. Cook Projecting future complications of chronic hepatitis C in the United States Liver Tranpl 9 2003 331 338
4. G.L. Davis, M.J. Alter, H. El-Serag Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression Gastroenterology 138 2010 513 521
5. S. Deuffic-Burban, P. Deltenre, A. Louvet Impact of viral eradication on mortality related to hepatitis C: a modeling approach in France J Hepatol 49 2008 175 183
6. J. Wong, G.M. McQuillan, J.G. McHutchinson Estimating future hepatitis C morbidity, mortality, and costs in the United States Am J Public Health 90 2000 1562 1569
7. V. Sypsa, G. Touloumi, G.V. Papatheodoridis Future trends of HCV-related cirrhosis and hepatocellular carcinoma under the currently available treatments J Viral Hepat 12 2005 543 550
8. M.W. Fried, M.L. Shiffman, K.R. Reddy Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection N Engl J Med 347 2002 975 982
9. M. Manns, J.G. McHutchinson, S. Gordon Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial Lancet 358 2001 958 965
10. C. Hezode, N. Forestier, G. Dusheiko Telaprevir and peginterferon with or without ribavirin for chronic HCV infection N Engl J Med 360 2009 1839 1850
11. I.M. Jacobson, J.G. McHutchison, G. Dusheiko Telaprevir for previously untreated chronic hepatitis C virus infection N Engl J Med 364 2011 2405 2416
12. P.Y. Kwo, E.J. Lawitz, J. McCone Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial Lancet 376 2010 705 716
13. J.G. McHutchison, G.T. Everson, S.C. Gordon Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection N Engl J Med 360 2009 1827 1838
14. F. Poordad, J. McCone Jr, B.R. Bacon Boceprevir for untreated chronic HCV genotype 1 infection N Engl J Med 364 2011 1195 1206
15. K.E. Sherman, S.L. Flamm, N.H. Afdhal Response-guided telaprevir combination treatment for hepatitis C virus infection N Engl J Med 365 2011 1014 1024
16. B.R. Bacon, S.C. Gordon, E. Lawitz Boceprevir for previously treated chronic HCV genotype 1 infection N Engl J Med 364 2011 1207 1217
17. J.G. McHutchison, M.P. Manns, A.J. Muir Telaprevir for previously treated chronic HCV infection N Engl J Med 362 2010 1292 1303
18. S. Zeuzem, P. Andreone, S. Pol Telaprevir for retreatment of HCV infection N Engl J Med 364 2011 2417 2428
19. N. Muhlberger, R. Schwarzer, B. Lettmeier HCV-related burden of disease in Europe: a systematic assessment of incidence, prevalence, morbidity, and mortality BMC Public Health 9 2009 34
20. B. Lettmeier, N. Muhlberger, R. Schwarzer Market uptake of new antiviral drugs for the treatment of hepatitis C J Hepatol 49 2008 528 536
21. A. Mariano, C. Caserta, G.M. Pendino Antiviral treatment for hepatitis C virus infection: effectiveness at general population level in a highly endemic area Dig Liver Dis 41 2009 509 515
22. Centers for Disease Control and Prevention Disease burden from viral hepatitis A, B, and C in the United States http://www.cdc.gov/hepatitis/PDFs/ disease-burden.pdf
23. M.J. Sweeting, V.D. Hope, M. Hickman Hepatitis C infection among injecting drug users in England and Wales (1992-2006): there and back again? Am J Epidemiol 170 2009 352 360
24. C. Gerard, J. Delwaide, D. Vaira Evolution over a 10 year period of the epidemiological profile of 1,726 newly diagnosed HCV patients in Belgium J Med Virol 76 2005 503 510
25. T. Poynard, P. Bedossa, P. Opolon OBSVIRC, METAVIR, CLINIVIR, DOSVIRC Groups Natural history of liver fibrosis progression in patients with chronic hepatitis C Lancet 349 1997 825 832
26. F. Roudot-Thoraval, A. Bastie, J.M. Pawlotsky Epidemiological factors affecting the severity of hepatitis C virus-related liver disease: a French survey of 6,664 patients Hepatology 26 1997 485 490
27. M. Martinot-Peignoux, F. Roudot-Thoraval, I. Mendel Hepatitis C virus genotypes in France: relationship with epidemiology, pathogenicity and response to interferon therapy The GEMHEP. J Viral Hepat 6 1999 435 443
28. C. Payan, F. Roudot-Thoraval, P. Marcellin Changing of hepatitis C virus genotype patterns in France at the beginning of the third millenium: The GEMHEP GenoCII Study J Viral Hepat 12 2005 405 413
29. D. Huppe, E. Zehnter, S. Mauss Epidemiology of chronic hepatitis C in Germany - an analysis of 10,326 patients in hepatitis centres and outpatient unit [in German] Z Gastroenterol 46 2008 34 44
30. A. Mariano, G. Scalia Tomba, M.E. Tosti Estimating the incidence, prevalence and clinical burden of hepatitis C over time in Italy Scand J Infect Dis 41 2009 689 699
31. G. Matera, A. Lamberti, A. Quirino Changes in the prevalence of hepatitis C virus (HCV) genotype 4 in Calabria, Southern Italy Diagn Microbiol Infect Dis 42 2002 169 173
32. J.M. Echevarria, P. Leon, F. Pozo Follow-up of the prevalence of hepatitis C virus genotypes in Spain during a nine-year period (1996-2004) Enferm Infecc Microbiol Clin 24 2006 20 25
33. M.A. Serra, F. Rodriguez, J.A. del Olmo Influence of age and date of infection on distribution of hepatitis C virus genotypes and fibrosis stage J Viral Hepat 10 2003 183 188
34. Hepatitis C in the UK 2009 2009 Health Protection Agency Centre for Infections London, England
35. S.J. Hutchinson, K.M. Roy, S. Wadd Hepatitis C virus infection in Scotland: epidemiological review and public health challenges Scott Med J 51 2006 8 15
36. A.H. Mohsen Trent HCV Study Group The epidemiology of hepatitis C in a UK health regional population of 5.12 million Gut 48 2001 707 713
37. M. Cornberg, H.A. Razavi, A. Alberti A systematic review of hepatitis C virus epidemiology in Europe, Canada and Israel Liver Int 31 Suppl 2 2011 30 60
38. C. Meffre, Y. Le Strat, E. Delarocque-Astagneau Prevalence of hepatitis B and hepatitis C virus infections in France in 2004: social factors are important predictors after adjusting for known risk factors J Med Virol 82 2010 546 555
39. H. Carsauw, M. Adler, P. Goubau Investigations following the use of inactive batch of Cidex solution in Belgian hospitals Acta Gastroenterol Belg 66 2003 D35
40. E. Zehnter, S. Mauss, C. John Efficacy of peginterferon alfa-2a (40KD) and ribavirin in patients with chronic hepatitis C in Germany - a contribution to health care (abstr) Hepatology 42 2005 683A
41. The Hepatitis C Trust The UK vs. Europe: Losing the fight against hepatitis C 2006 University of Southampton London, England
42. M. Varela, M. Reig, M. de la Mata Treatment approach of hepatocellular carcinoma in Spain Analysis of 705 patients from 62 centers [in Spanish] Med Clin (Barc) 134 2010 569 576
43. A. Costella Health Protection Agency United Kingdom. Hepatitis C in the UK 2008. The Health Protection Agency Annual Report 2008 Health Protection Agency Centre for Infections London, England
44. D. Goldberg, G. Brown, S. Hutchinson Hepatitis C action plan for Scotland: phase II (May 2008-March 2011) Euro Surveill 13 2008
45. J.G. McHutchison, S.C. Gordon, E.R. Schiff Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C N Engl J Med 339 1998 1485 1492
46. A. Pariente, P. Lahmek, C. Duprat Treatment of chronic hepatitis C with pegylated interferon and ribavirin in treatment-naive patients in 'true life': a plea in favor of independent postmarketing evaluations Eur J Gastroenterol Hepatol 22 2010 1297 1302
47. S.W. Schalm, O. Weiland, B.E. Hansen Interferon-ribavirin for chronic hepatitis C with and without cirrhosis: analysis of individual patient data of six controlled trials Gastroenterology 117 1999 408 413
48. J.G. McHutchison, E.J. Lawitz, M.L. Shiffman Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection N Engl J Med 361 2009 580 593
49. S. Pol, R.H. Ghalib, V.K. Rustgi First report of SVR12 for a NS5A replication complex inhibitor, BMS-790052 in combination with PEG-IFNα-2a and RBV: Phase 2a trial in treatment-naive HCV-genotype 1 subjects J Hepatol 54 2011 S544 S545
50. E. Lawitz, J.P. Lalezari, T. Hassanein Once-daily PSI-7977 plus Peg/RBV in treatment-naïve patients with HCV GT1: robust end of treatment response rates are sustained post-treatment (PROTON) (abstr) Hepatology 54 2011 472A
51. K. Chayama, S. Takahashi, J. Toyota Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b-infected null responders Hepatology 55 2012 742 748
52. A.S. Lok, D.F. Gardiner, E. Lawitz Preliminary study of two antiviral agents for hepatitis C genotype 1 N Engl J Med 366 2012 216 224
53. E.J. Gane, C. Stedman, R.H. Hyland Once daily PSI-7977 plus RBV: pegylated interferon-alpha not required for complete rapid viral response in treatment-naive patients with HCV GT2 or GT3 (abstr) Hepatology 54 2011 377A
54. Y. Futagawa, P.I. Terasaki, K. Waki No improvement in long-term liver transplant graft survival in the last decade: an analysis of the UNOS data Am J Transplant 6 2006 1398 1406
55. D. Samuel, X. Forns, M. Berenguer Report of the monothematic EASL conference on liver transplantation for viral hepatitis (Paris, France, January 12-14, 2006) J Hepatol 45 2006 127 143
56. L. Pagliaro, V. Peri, C. Linea Natural history of chronic hepatitis C Ital J Gastroenterol Hepatol 31 1999 28 44
57. T. Poynard, V. Ratziu, F. Charlotte Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis C J Hepatol 34 2001 730 739
58. L. Serfaty, H. Aumaitre, O. Chazouilleres Determinants of outcome of compensated hepatitis C virus-related cirrhosis Hepatology 27 1998 1435 1440
59. G. Corrao, S. Arico Independent and combined action of hepatitis C virus infection and alcohol consumption on the risk of symptomatic liver cirrhosis Hepatology 27 1998 914 919
60. A.G. Singal, M.L. Volk, D. Jensen A sustained viral response is associated with reduced liver-related morbidity and mortality in patients with hepatitis C virus Clin Gastroenterol Hepatol 8 2010 280 288 288 e1
61. F. Degos, C. Christidis, N. Ganne-Carrié Hepatitis C virus related cirrhosis: time to occurrence of hepatocellular carcinoma and death Gut 47 2000 131 136
62. G. D'Amico, G. Garcia-Tsao, L. Pagliaro Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies J Hepatol 44 2006 217 231
63. H.B. El-Serag, A.C. Mason, C. Key Trends in survival of patients with hepatocellular carcinoma between 1977 and 1996 in the United States Hepatology 33 2001 62 65
64. H.B. El-Serag Hepatocellular carcinoma: recent trends in the United States Gastroenterology 127 2004 S27 S34
65. S. Rossol Chronic HCV infections A model disease for therapy, economics and social-medical aspects [in German] Gesundheitswesen 69 2007 146 150
66. E. Zehnter, S. Mauss, C. John Efficacy of peginterferon alfa-2a (40KD) and ribavirin in patients with chronic hepatitis C in Germany - a contribution to health care (abstr) Hepatology 42 2005 683A
67. The Hepatitis C Trust The UK vs. Europe: losing the fight against hepatitis C 2006 University of Southampton London, England
68. M. Cornberg, H.A. Razavi, A. Alberti A systematic review of hepatitis C virus epidemiology in Europe, Canada and Israel Liver Int 31 Suppl 2 2011 30 60
69. M. Varela, M. Reig, M. de la Mata Treatment approach of hepatocellular carcinoma in Spain Analysis of 705 patients from 62 centers [in Spanish] Med Clin (Barc) 134 2010 569 576
70. M. Bourliere, D. Ouzan, M. Rosenheim Efficacy of peginterferon alpha-2a and ribavirin in 2101 patients with HCV infection in real-life clinical practice: results of the French HEPATYS study (abstr) Hepatology 46 2007 366A
71. S. Deuffic, L. Buffat, T. Poynard Modeling the hepatitis C virus epidemic in France Hepatology 29 1999 1596 1601
72. H. Van Vlierberghe, I. Colle, J. Henrion The HepCar registry: report on a one-year registration program of hepatocellular carcinoma (HCC) in Belgium What is daily practice in HCC? Acta Gastroenterol Belg 68 2005 403 411
73. P. Marcellin, F. Pequignot, E. Delarocque-Astagneau Mortality related to chronic hepatitis B and chronic hepatitis C in France: Evidence for the role of HIV coinfection and alcohol consumption J Hepatol 48 2008 200 207
74. S. Kubicka, K.L. Rudolph, M. Hanke Hepatocellular carcinoma in Germany: a retrospective epidemiological study from a low-endemic area Liver 20 2000 312 318
75. C. Rabe, T. Pilz, C. Klostermann Clinical characteristics and outcome of a cohort of 101 patients with hepatocellular carcinoma World J Gastroenterol 7 2001 208 215
76. T. Stroffolini, P. Andreone, A. Andriulli Characteristics of hepatocellular carcinoma in Italy J Hepatol 29 1998 944 952
77. T. Stroffolini, F. Trevisani, G. Pinzello Changing aetiological factors of hepatocellular carcinoma and their potential impact on the effectiveness of surveillance Dig Liver Dis 43 2011 875 880
78. A. Mariano, G. Scalia Tomba, M.E. Tosti Estimating the incidence, prevalence and clinical burden of hepatitis C over time in Italy Scand J Infect Dis 41 2009 689 699
79. Hepatitis C in the UK 2009 2009 Health Protection Agency Centre for Infections London, England
80. D. Marquardt An algorithm for least-squares estimation of nonlinear parameters J Soc Indust Appl Math 11 1963 431 441
81. K.W. Fong, T.H. Jefferson, T. Suyehiro et al. SLATEC Common Mathematical Library, 1993 http://www.netlib.org/slatec/guide
82. A. Aronsohn, I. Ancuta, F. Caruntu Impact of age >65 years on SVR and relapse in chronic hepatitis C (CHC) patients (pts) treated with peginterferon alfa-2a (40KD) (PegIFNα2a[40KD]) plus ribavirin (RBV): Final analysis from the large multinational real-world PROPHESYS cohorts Hepatology 54 2011 836A
83. T. Stroffolini, F. Trevisani, G.B. Pinzello Changing aetiological factors of hepatocellular carcinoma and their potential impact on the effectiveness of surveillance Dig Liver Dis 43 2011 875 880
84. M. Beutels, P. Van Damme, W. Aelvoet Prevalence of hepatitis A, B and C in the Flemish population Eur J Epidemiol 13 1997 275 280
85. C. Meffre, Y. Le Strat, E. Delarocque-Astagneau Prevalence of hepatitis B and hepatitis C virus infections in France in 2004: social factors are important predictors after adjusting for known risk factors J Med Virol 82 2010 546 555
86. W. Thierfelder, W. Hellenbrand, H. Meisel Prevalence of markers for hepatitis A, B and C in the German population Results of the German National Health Interview and Examination Survey 1998 Eur J Epidemiol 17 2001 429 435
87. K.D. Palitzsch, B. Hottentrager, K. Schlottmann Prevalence of antibodies against hepatitis C virus in the adult German population Eur J Gastroenterol Hepatol 11 1999 1215 1220
88. F. Ansaldi, B. Bruzzone, S. Salmaso Different seroprevalence and molecular epidemiology patterns of hepatitis C virus infection in Italy J Med Virol 76 2005 327 332
89. M.M. Chimeno, A. Chocarro, P. Brezmes Seroprevalence of hepatitis C virus in the general population [in Spanish] Enferm Infecc Microbiol Clin 20 2002 64 67
90. A. Dominguez, M. Bruguera, J. Vidal Community-based seroepidemiological survey of HCV infection in Catalonia, Spain J Med Virol 65 2001 688 693
91. A. Garcia-Fulgueiras, M.J. Tormo, T. Rodriguez Prevalence of hepatitis B and C markers in the south-east of Spain: an unlinked community-based serosurvey of 2,203 adults Scand J Infect Dis 28 1996 17 20
92. R. Lopez-Izquierdo, M.A. Udaondo, P. Zarzosa Seroprevalence of viral hepatitis in a representative general population of an urban public health area in Castilla y Leon (Spain) [in Spanish] Enferm Infecc Microbiol Clin 25 2007 317 323
93. J.J. Prieto Domingo, J.A. Carrion Bolanos, F. Bandres Moya Prevalence of hepatitis C virus and excessive consumption of alcohol in a nonhospital worker population [in Spanish] Gastroenterol Hepatol 20 1997 479 483
94. S. Riestra, E. Fernandez, P. Leiva Prevalence of hepatitis C virus infection in the general population of northern Spain Eur J Gastroenterol Hepatol 13 2001 477 481
95. B. Sacristan, M.I. Gastanares, A. Elena Seroepidemiologic study of hepatitis C virus infection in a general population from the region of La Rioja, Spain [in Spanish] Med Clin (Barc) 107 1996 331 335
96. U. Gungabissoon, M.A. Balogun, M.E. Ramsay Hepatitis C virus: laboratory surveillance in England and Wales, 1992-2004 Epidemiol Infect 135 2007 541 548
97. Hepatitis C action plan for Scotland phase II: May 2008 - March 2011 2008 The Scottish Government Edinburgh, Scotland
98. C. Gerard, J. Delwaide, D. Vaira Evolution over a 10 year period of the epidemiological profile of 1,726 newly diagnosed HCV patients in Belgium J Med Virol 76 2005 503 510
99. M. Martinot-Peignoux, F. Roudot-Thoraval, I. Mendel Hepatitis C virus genotypes in France: relationship with epidemiology, pathogenicity and response to interferon therapy The GEMHEP. J Viral Hepat 6 1999 435 443
100. C. Payan, F. Roudot-Thoraval, P. Marcellin Changing of hepatitis C virus genotype patterns in France at the beginning of the third millenium: the GEMHEP GenoCII Study J Viral Hepat 12 2005 405 413
101. D. Huppe, E. Zehnter, S. Mauss Epidemiology of chronic hepatitis C in Germany - an analysis of 10,326 patients in hepatitis centres and outpatient units [in German] Z Gastroenterol 46 2008 34 44
102. G. Matera, A. Lamberti, A. Quirino Changes in the prevalence of hepatitis C virus (HCV) genotype 4 in Calabria, Southern Italy Diagn Microbiol Infect Dis 42 2002 169 173
103. M.A. Serra, F. Rodriguez, J.A. del Olmo Influence of age and date of infection on distribution of hepatitis C virus genotypes and fibrosis stage J Viral Hepat 10 2003 183 188
104. J.M. Echevarria, P. Leon, F. Pozo Follow-up of the prevalence of hepatitis C virus genotypes in Spain during a nine-year period (1996-2004) Enferm Infecc Microbiol Clin 24 2006 20 25
105. A.H. Mohsen Trent HCV Study Group The epidemiology of hepatitis C in a UK health regional population of 5.12 million Gut 48 2001 707 713
106. S.J. Hutchinson, K.M. Roy, S. Wadd Hepatitis C virus infection in Scotland: epidemiological review and public health challenges Scott Med J 51 2006 8 15
107. H. Carsauw, M. Adler, P. Goubau Investigations following the use of inactive batch of Cidex solution in Belgian hospitals Acta Gastroenterol Belg 66 2003 D35
108. A. Mariano, C. Caserta, G.M. Pendino Antiviral treatment for hepatitis C virus infection: effectiveness at general population level in a highly endemic area Dig Liver Dis 41 2009 509 515
109. A. Costella Health Protection Agency United Kingdom. Hepatitis C in the UK 2008. The Health Protection Agency Annual Report 2008 Health Protection Agency Centre for Infections London, England
110. D. Goldberg, G. Brown, S. Hutchinson Hepatitis C action plan for Scotland: phase II (May 2008-March 2011) Euro Surveill 13 2008
111. Sales Data 2006 IMS Health IMS MIDAS/Q1 2006
112. Groupement pour l'Elaboration et la Réalisation de Statistiques Sales data 2006
113. S. De Maeght, J. Henrion, N. Bourgeois A pilot observational survey of hepatitis C in Belgium Acta Gastroenterol Belg 71 2008 4 8
114. A. Pariente, P. Lahmek, C. Duprat Treatment of chronic hepatitis C with pegylated interferon and ribavirin in treatment-naive patients in 'true life': a plea in favor of independent postmarketing evaluations Eur J Gastroenterol Hepatol 22 2010 1297 1302
115. Consell Assessor sobre el tractament farmacologic de les hepatitis viriques Informe d'activitats: any 2007 In: Generalitat de Catalunya, Departament de Salut, Direccio General de Recursos Sanitaris http://www20.gencat.cat/docs/canalsalut/Home%20Canal%20Salut/Professionals/ Desenvolupament-professional/Grups-de-treball/pdf/infoacti07.pdf ed. Barcelona, March 2008.
116. S. Pol, R.H. Ghalib, V.K. Rustgi First report of SVR12 for a NS5A replication complex inhibitor, BMS-790052 in combination with PEG-IFNα-2a and RBV: Phase 2a trial in treatment-naive HCV-genotype 1 subjects J Hepatol 54 2011 S544 S545
117. E. Lawitz, J.P. Lalezari, T. Hassanein Once-daily PSI-7977 plus Peg/RBV in treatment-naïve patients with HCV GT1: robust end of treatment response rates are sustained post-treatment (PROTON) (abstr) Hepatology 54 2011 472A
118. K. Chayama, S. Takahashi, J. Toyota Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b-infected null responders Hepatology 55 2012 742 748
119. A.S. Lok, D.F. Gardiner, E. Lawitz Preliminary study of two antiviral agents for hepatitis C genotype 1 N Engl J Med 366 2012 216 224
120. E.J. Gane, C. Stedman, R.H. Hyland Once daily PSI-7977 plus RBV: pegylated interferon-alpha not required for complete rapid viral response in treatment-naive patients with HCV GT2 or GT3 Hepatology 54 2011 377A